Chinese Clinical Practice Guideline for the Management of "CKD-PeriDialysis"-the Periods Prior to and in the Early-Stage of Initial Dialysis

被引:11
作者
Mei, Changlin [1 ]
机构
[1] Navy Mil Med Univ, Shanghai Changzheng Hosp, 415 Fengyang Rd, Shanghai, Peoples R China
关键词
chronic kidney disease; CKD PeriDialysis period; complication; end stage kidney disease; replacement treatment; CHRONIC KIDNEY-DISEASE; BONE ALKALINE-PHOSPHATASE; INTRADIALYTIC HYPOTENSION; PERITONEAL-DIALYSIS; RENAL-DISEASE; ONLINE HEMODIAFILTRATION; DISTAL REVASCULARIZATION; INTERNATIONAL SOCIETY; HEMODIALYSIS-PATIENTS; DIAGNOSTIC-CRITERIA;
D O I
10.1016/j.ekir.2022.10.001
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The National Experts Group on Nephrology have developed these guidelines to improve the management of pre-dialysis and initial dialysis patients with chronic kidney disease (CKD) (two periods contiguous with dialysis initiation termed here 'PeriDialysis CKD'). The pre-dialysis period is variable, whereas the initial dialysis period is more fixed at 3 months to 6 months after initiating dialysis. The new concept and characteristics of 'CKD-PeriDialysis' are proposed in the guideline. During the CKD-PeriDialysis period, the incidence rate of complications, mortality and treatment cost significantly increases and the glomerular filtration rate (GFR) rapidly decreases, which requires intensive management. The guideline systematically and comprehensively elaborates the recommendations for indicators to be used in for disease evaluation, timing and mode selection of renal replacement therapy, dialysis adequacy evaluation, and diagnosis and treatment of common PeriDialysis complications. Finally, future research directions of CKD-PeriDialysis are proposed. CKD-PeriDialysis management is a difficult clinical issue in kidney disease, and the development and implementation of these guidelines is important to improve the management of CKD-PeriDialysis patients in China, which could ultimately improve survival rates and quality of life, and reduce the medical burden.
引用
收藏
页码:S531 / S558
页数:28
相关论文
共 134 条
[1]   Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan [J].
Akizawa, Tadao ;
Iwasaki, Manabu ;
Yamaguchi, Yusuke ;
Majikawa, Yoshikatsu ;
Reusch, Michael .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 31 (07) :1628-1639
[2]   A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naive Chronic Kidney Disease Patients Not on Dialysis [J].
Akizawa, Tadao ;
Yamaguchi, Yusuke ;
Otsuka, Tetsuro ;
Reusch, Michael .
NEPHRON, 2020, 144 (08) :372-382
[3]   Distal Revascularization and Interval Ligation for the Management of Dialysis Access Steal Syndrome [J].
Alie-Cusson, Fanny S. ;
Bhat, Karthik ;
Ramchandani, Juhi ;
Steerman, Samuel N. ;
Dexter, David J. ;
Panneton, Jean M. .
ANNALS OF VASCULAR SURGERY, 2021, 74 :29-35
[5]  
[Anonymous], 2019, Diabetes Care, V42, P1, DOI 10.2337/dc19-ti01
[6]  
[Anonymous], BIOIMP DEV ASS BOD F
[7]  
[Anonymous], 2012, Kidney Int. Suppl
[8]  
[Anonymous], ANN PUBL COMM STAND
[9]  
[Anonymous], 2010, Part 2: Total Phosphorus Content
[10]  
[Anonymous], ENTR SAC VALS CHRON